Patents Assigned to Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V.
  • Patent number: 5438121
    Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen.
    Type: Grant
    Filed: April 25, 1991
    Date of Patent: August 1, 1995
    Assignees: Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V., Regeneron Pharmaceuticals, Inc.
    Inventors: Yves-Alain Barde, Joachim Leibrock, Friedrich Lottspeich, David Edgar, George Yancopoulos, Hans Thoenen